6.735
price up icon3.52%   0.195
 
loading
전일 마감가:
$6.54
열려 있는:
$6.53
하루 거래량:
110.54K
Relative Volume:
0.48
시가총액:
$90.23M
수익:
-
순이익/손실:
$-56.20M
주가수익비율:
-1.8866
EPS:
-3.57
순현금흐름:
$-39.97M
1주 성능:
-2.87%
1개월 성능:
-31.06%
6개월 성능:
-17.74%
1년 성능:
+2.58%
1일 변동 폭
Value
$6.367
$6.89
1주일 범위
Value
$6.367
$7.12
52주 변동 폭
Value
$4.53
$22.49

Annovis Bio Inc Stock (ANVS) Company Profile

Name
명칭
Annovis Bio Inc
Name
전화
484-875-3192
Name
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Name
직원
6
Name
트위터
Name
다음 수익 날짜
2024-12-11
Name
최신 SEC 제출 서류
Name
ANVS's Discussions on Twitter

ANVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
ANVS 6.735 90.23M 0 -56.20M -39.97M -3.57
VRTX 449.99 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.40 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 593.04 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.04 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.32 24.89B 3.30B -501.07M 1.03B 11.54

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-07-07 재확인 Maxim Group Buy

Annovis Bio Inc 주식(ANVS)의 최신 뉴스

pulisher
Nov 20, 2024

Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MSN

Nov 20, 2024
pulisher
Nov 17, 2024

Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN

Nov 17, 2024
pulisher
Nov 17, 2024

When the Price of (ANVS) Talks, People Listen - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart

Nov 14, 2024
pulisher
Nov 14, 2024

Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail

Nov 14, 2024
pulisher
Nov 14, 2024

Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 12, 2024

Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart

Nov 12, 2024
pulisher
Nov 12, 2024

Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo

Nov 12, 2024
pulisher
Nov 12, 2024

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire

Nov 12, 2024
pulisher
Nov 11, 2024

Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart

Nov 11, 2024
pulisher
Nov 11, 2024

Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq

Nov 11, 2024
pulisher
Nov 11, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance

Nov 11, 2024
pulisher
Nov 08, 2024

Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Nov 07, 2024

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist - citybiz

Nov 07, 2024
pulisher
Nov 06, 2024

Annovis Bio (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease Conference - Barchart

Nov 06, 2024
pulisher
Nov 06, 2024

(ANVS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 06, 2024
pulisher
Oct 31, 2024

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire

Oct 31, 2024
pulisher
Oct 30, 2024

Annovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients - Barchart

Oct 30, 2024
pulisher
Oct 28, 2024

Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) PT at $32.17 - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart

Oct 24, 2024
pulisher
Oct 22, 2024

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times

Oct 22, 2024
pulisher
Oct 19, 2024

Annovis Bio files three drug patents - Pennsylvania Business Report

Oct 19, 2024
pulisher
Oct 17, 2024

Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha

Oct 17, 2024
pulisher
Oct 17, 2024

Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha

Oct 17, 2024
pulisher
Oct 17, 2024

Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India

Oct 16, 2024
pulisher
Oct 16, 2024

Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart

Oct 16, 2024
pulisher
Oct 16, 2024

Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex

Oct 16, 2024
pulisher
Oct 16, 2024

Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

(ANVS) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 15, 2024

Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo

Oct 15, 2024
pulisher
Oct 15, 2024

Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph

Oct 15, 2024
pulisher
Oct 15, 2024

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire

Oct 15, 2024
pulisher
Oct 10, 2024

Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo

Oct 10, 2024

Annovis Bio Inc (ANVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):